Print Issue: October 01, 2006

BPH Treatment Device Returns to Market

Celsion Corporation of Columbia, Md., has announced it will resume shipments of its Prolieve Thermodilatation system for benign prostatic hyperplasia after clearance from the FDA’s Center for Devices and Radiological Health.

Expectant Management A Viable Option

ATLANTA—Delayed intervention for treating small renal masses may be appropriate for selected patients, especially those with competing comorbidities, a study found. This conservative approach has little adverse effect on pathological and clinical outcomes, researchers note.

Next post in News